XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 13.87%350.02B | 11.77%96.47B | 15.09%88.27B | 13.59%84.74B | 15.41%80.54B | 8.68%307.39B | 13.49%86.31B | 11.00%76.69B | 7.06%74.6B | 2.61%69.79B |
Operating revenue | 13.87%350.02B | 11.77%96.47B | 15.09%88.27B | 13.59%84.74B | 15.41%80.54B | 8.68%307.39B | 13.49%86.31B | 11.00%76.69B | 7.06%74.6B | 2.61%69.79B |
Cost of revenue | 9.73%146.31B | 8.09%40.61B | 9.77%36.47B | 11.25%35.51B | 10.13%33.71B | 5.65%133.33B | 6.32%37.58B | 6.65%33.23B | 6.02%31.92B | 3.42%30.61B |
Gross profit | 17.03%203.71B | 14.61%55.86B | 19.17%51.79B | 15.34%49.24B | 19.53%46.83B | 11.13%174.06B | 19.72%48.74B | 14.58%43.46B | 7.85%42.69B | 1.99%39.18B |
Operating expense | 1.73%91.32B | -0.62%24.88B | 5.21%23.27B | 4.60%21.81B | -1.86%21.36B | 9.75%89.77B | 11.05%25.04B | 6.36%22.12B | 3.59%20.85B | 18.79%21.76B |
Selling and administrative expenses | -5.29%42B | -8.95%11.77B | -0.34%10.83B | -3.04%9.95B | -8.16%9.45B | 4.85%44.34B | 5.26%12.93B | 3.20%10.86B | -0.24%10.26B | 11.88%10.29B |
-Selling and marketing expense | -0.39%27.81B | -4.61%7.36B | 4.98%7.23B | 0.16%6.79B | -1.64%6.43B | 5.08%27.92B | 7.46%7.72B | -0.65%6.88B | 2.28%6.78B | 12.15%6.53B |
-General and administrative expense | -13.62%14.19B | -15.39%4.41B | -9.55%3.6B | -9.28%3.16B | -19.50%3.03B | 4.46%16.43B | 2.16%5.21B | 10.62%3.98B | -4.81%3.48B | 11.41%3.76B |
Research and development costs | 8.58%49.33B | 8.28%13.12B | 10.56%12.45B | 12.01%11.86B | 3.79%11.9B | 15.01%45.43B | 17.98%12.11B | 9.59%11.26B | 7.59%10.59B | 25.76%11.47B |
Operating profit | 33.33%112.39B | 30.70%30.97B | 33.63%28.52B | 25.58%27.43B | 46.26%25.47B | 12.63%84.29B | 30.49%23.7B | 24.56%21.34B | 12.26%21.84B | -13.33%17.42B |
Net non-operating interest income expense | 18.47%4.21B | -0.58%1.04B | 25.16%1.19B | 20.49%1.02B | 34.87%967M | 95.76%3.56B | 82.95%1.04B | 84.82%950M | 110.67%849M | 116.62%717M |
Non-operating interest income | 15.96%4.48B | -1.98%1.09B | 16.60%1.24B | 22.20%1.09B | 33.12%1.06B | 77.78%3.87B | 68.44%1.11B | 73.33%1.07B | 83.54%892M | 92.51%797M |
Non-operating interest expense | -12.99%268M | -23.19%53M | -53.45%54M | 55.81%67M | 17.50%94M | -13.73%308M | -23.33%69M | 14.85%116M | -48.19%43M | -3.61%80M |
Other net income (expense) | 250.54%3.21B | 172.39%236M | 282.12%2B | -14.41%-897M | 2,469.86%1.88B | 59.99%-2.13B | 79.39%-326M | 22.60%-1.1B | 6.89%-784M | 104.90%73M |
Gain on sale of security | 209.75%2.26B | -500.00%-88M | 269.83%2B | -54.05%-1.2B | 1,324.60%1.54B | 66.61%-2.06B | 101.19%22M | 22.06%-1.18B | 40.28%-777M | 91.66%-126M |
Earnings from equity interest | 70.06%-188M | 66.02%-87M | 50.23%-107M | 130.19%32M | 49.02%-26M | -86.35%-628M | -725.81%-256M | -117.17%-215M | 10.17%-106M | 42.70%-51M |
Other non- operating income (expenses) | 104.50%1.14B | 546.74%411M | -66.89%99M | 170.71%268M | 43.60%359M | -52.84%556M | -130.98%-92M | 51.78%299M | -82.84%99M | 131.48%250M |
Income before tax | 39.78%119.82B | 32.08%32.24B | 49.58%31.71B | 25.79%27.55B | 55.53%28.32B | 20.17%85.72B | 42.37%24.41B | 30.58%21.2B | 15.19%21.9B | -3.85%18.21B |
Income tax | 65.22%19.7B | 53.21%5.71B | 258.42%5.41B | 11.23%3.93B | 47.53%4.65B | 4.98%11.92B | 5.73%3.73B | -35.08%1.51B | 17.36%3.54B | 26.26%3.15B |
Net income | 35.67%100.12B | 28.27%26.54B | 33.58%26.3B | 28.59%23.62B | 57.21%23.66B | 23.05%73.8B | 51.84%20.69B | 41.55%19.69B | 14.79%18.37B | -8.43%15.05B |
Net income continuous Operations | 35.67%100.12B | 28.27%26.54B | 33.58%26.3B | 28.59%23.62B | 57.21%23.66B | 23.05%73.8B | 51.84%20.69B | 41.55%19.69B | 14.79%18.37B | -8.43%15.05B |
Minority interest income | ||||||||||
Net income attributable to the parent company | 35.67%100.12B | 28.27%26.54B | 33.58%26.3B | 28.59%23.62B | 57.21%23.66B | 23.05%73.8B | 51.84%20.69B | 41.55%19.69B | 14.79%18.37B | -8.43%15.05B |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 35.67%100.12B | 28.27%26.54B | 33.58%26.3B | 28.59%23.62B | 57.21%23.66B | 23.05%73.8B | 51.84%20.69B | 41.55%19.69B | 14.79%18.37B | -8.43%15.05B |
Basic earnings per share | 39.21%8.13 | 30.72%2.17 | 37.18%2.14 | 31.72%1.91 | 61.86%1.91 | 27.23%5.84 | 56.60%1.66 | 45.79%1.56 | 18.85%1.45 | -4.84%1.18 |
Diluted earnings per share | 38.62%8.04 | 31.10%2.15 | 36.77%2.12 | 31.25%1.89 | 61.54%1.89 | 27.19%5.8 | 56.19%1.64 | 46.23%1.55 | 19.01%1.44 | -4.88%1.17 |
Dividend per share | 0.6 | 0.2 | 0.2 | 0.2 | ||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |